Mohamed was appointed group CEO of Mubadala Bio upon launch in 2025 as a wholly owned subsidiary of Mubadala Investment Company. It operates across integrated biopharma manufacturing and pharma logistics, with a portfolio of eight manufacturing companies across Asia, Africa, and Europe – four of which are in the UAE, serving over 50 countries. In 2026, Mubadala Bio completed the acquisition of Al Ittihad Drug Store (IDS) and Global Medical Supply Chain (GMSC). In July 2026, it launched eight haemodialysis products through its subsidiary Wellpharma, marking the UAE’s first local manufacturing of haemodialysis concentrate solutions. Before Mubadala Bio, Mohamed was the CEO of Julphar.